Pharma News

Keep updating your pharma knowledge
biosimilar course
10 Dec 2014

Zydus Cadila to launch the biosimilar of Adalimumab in India

Zydus Cadila launched the biosimilar of Adalimumab – the world’s largest selling therapy. Developed by the researchers at the Zydus Research Centre, the biosimilar has been approved by the Drug Controller General of India and will be marketed under the brand name, Exemptia to treat auto immune disorders such as rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, and Ankylosing Spondylitis.

This novel non-infringing process for Adalimumab and a novel non-infringing formulation has been researched, developed and produced by scientists at the Zydus Research Centre. The biosimilar is the first to be launched by any company in the world and is a ‘fingerprint match’ with the originator in terms of safety, purity and potency of the product. The biosimilar of adalimumab is a part of Zydus’ robust biologics programme which has the largest number of
monoclonal antibodies under development in India. The group’s R&D pipeline which comprises 24 biologics includes biosimilars and three novel biologics. These biologics are being developed to treat auto immune disorders like arthritis, cancer, infertility and stroke.

Zydus will offer a dedicated Exemptia Care support programme to patients and caregivers. The programme shall provide important support and information regarding access, adherence, awareness and thereby help patients to appropriately manage their disease. The therapy will be marketed by Zydus Biovation – a new division launched to exclusively market this ground breaking therapy. The launch of Exemptia begins with a series of CMEs and scientific symposia to highlight the gaps in the current management of auto immune disorders.


Ref: Press Release of Zydus Cadila, Zydus launches world’s first biosimilar of Adalimumab, on 9th of December, 2014.

1 Response

Leave a Reply

The reCAPTCHA verification period has expired. Please reload the page.

Upskill Your Pharma Knowledge

Explore Next Gen Learning

Case Studies & Caselets | Simulation Based Learning | E-Lectures | Online Self Competency Assessments

Thank You for Subscription!